Abstract:RET (rearranged during transfection), encoding a tyrosine kinase receptor, is a novel therapeutic target for cancers. The aberrations of RET are commonly found in cancers. Here, we profiled a comprehensive genomic landscape of RET mutations, copy number variants (CNVs), co-occurrence of RET and its mRNA expression and methylation levels in pan cancer, paving the way to the development of new RET-targeted therapies in clinic. Analysis of RET somatic mutations, CNVs, co-occurrence, mRNA expression and methylation were performed among 32 cancer types from The Cancer Genome Atlas (TCGA) dataset covering a total of 10,953 patients with 10,967 samples. RET aberrations were found in 3.0% of diverse cancers. The top two RET-altered tumors were skin cutaneous melanoma (SKCM) and uterine corpus endometrial carcinoma (UCEC) with dominant mutations in the other and PKinase_Tyr domains. RET-G823E and RET-S891L were most commonly found in SKCM and UCEC. Thyroid carcinoma (THCA) demonstrated the highest rate of coiled-coil domain containing 6 (CCDC6)-RET fusions, which constitutively activate RET kinase. Two FDA-approved RET inhibitors—pralsetinib and selpercatinib have been implied for the treatment of patients with RET S891L mutant UCEC and the treatment of patients with metastatic RET-fusion positive THCA and non-small cell lung cancer (NSCLC) at therapeutic level 1. We also identified four RET M918T-altered cases in patients with pheochromocytoma and paraganglioma (PCPG), which may induce drug resistance against multikinase inhibitors. Next, 273 co-occurring aberrations, most frequently in Notch signaling, TGF-β pathway, cell cycle, and Ras-Raf-MEK-Erk/JNK signaling, were uncovered among 311 RET altered cases. TP53 mutations (162 patients) leads to the most significant co-occurrence associated with RET aberrations. Furthermore, the RET expression was found most significantly increased in breast invasive carcinoma (BRCA) and neck squamous cell carcinoma (HNSC), as compared to their corresponding normal tissues. At last, patients with higher expression and sequence variant frequency have a worse prognosis, such as sarcoma patients. This work provided a profound and comprehensive analysis of RET and co-occurred alterations, RET mRNA expression and the clinical significance in pan cancer, offering new insights into targeted therapy for patients with RET anomalies.

Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-center Retrospective Cohort Study in a Chinese Population

RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients

Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage

Genetic landscape of papillary thyroid carcinoma in the Chinese population

Association Between BRAF and RAS Mutations, and RET Rearrangements and the Clinical Features of Papillary Thyroid Cancer.

Next-Generation sequencing genomic landscape of Chinese thyroid tumors

KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.

Clinical and Sonographic Differences Between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma

Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

RET/PTC Rearrangement Affects Multifocal Formation of Papillary Thyroid Carcinoma

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients

Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.

Targeted Next Generation Sequencing Identifies Somatic Mutations and Gene Fusions in Papillary Thyroid Carcinoma

An integrative pan cancer analysis of RET aberrations and their potential clinical implications

BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients

[Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAF(V600E) Mutation and Rearranged During Transfection Proto-Oncogene Protein Expression].

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of NSCLC

Real world data analysis of next-generation sequencing and corresponding clinical characteristics in thyroid tumor

Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer